NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD
42.86
-0.86 (-1.97%)
The current stock price of EXEL is 42.86 USD. In the past month the price increased by 15.18%. In the past year, price increased by 108.36%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.77 | 322.91B | ||
AMGN | AMGEN INC | 13.1 | 146.19B | ||
GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
NTRA | NATERA INC | N/A | 20.73B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
BIIB | BIOGEN INC | 7.98 | 18.51B |
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502 US
CEO: Michael M. Morrissey
Employees: 1147
Phone: 16508377000
The current stock price of EXEL is 42.86 USD. The price decreased by -1.97% in the last trading session.
The exchange symbol of EXELIXIS INC is EXEL and it is listed on the Nasdaq exchange.
EXEL stock is listed on the Nasdaq exchange.
26 analysts have analysed EXEL and the average price target is 38.71 USD. This implies a price decrease of -9.69% is expected in the next year compared to the current price of 42.86. Check the EXELIXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EXELIXIS INC (EXEL) has a market capitalization of 11.81B USD. This makes EXEL a Large Cap stock.
EXELIXIS INC (EXEL) currently has 1147 employees.
EXELIXIS INC (EXEL) has a support level at 42.85. Check the full technical report for a detailed analysis of EXEL support and resistance levels.
The Revenue of EXELIXIS INC (EXEL) is expected to grow by 8.42% in the next year. Check the estimates tab for more information on the EXEL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EXEL does not pay a dividend.
EXELIXIS INC (EXEL) will report earnings on 2025-08-04, after the market close.
The PE ratio for EXELIXIS INC (EXEL) is 19.48. This is based on the reported non-GAAP earnings per share of 2.2 and the current share price of 42.86 USD. Check the full fundamental report for a full analysis of the valuation metrics for EXEL.
The outstanding short interest for EXELIXIS INC (EXEL) is 7.12% of its float. Check the ownership tab for more information on the EXEL short interest.
ChartMill assigns a technical rating of 10 / 10 to EXEL. When comparing the yearly performance of all stocks, EXEL is one of the better performing stocks in the market, outperforming 96.84% of all stocks.
ChartMill assigns a fundamental rating of 8 / 10 to EXEL. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months EXEL reported a non-GAAP Earnings per Share(EPS) of 2.2. The EPS increased by 205.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 24.04% | ||
ROA | 17.68% | ||
ROE | 23.23% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 77% to EXEL. The Buy consensus is the average rating of analysts ratings from 26 analysts.
For the next year, analysts expect an EPS growth of 22.46% and a revenue growth 8.42% for EXEL